Seroprevalence in Canada – New Data from CITF

Posted on July 19, 2023 by pathwp

“In order to tailor public health strategies to the current pandemic context, it is important to understand the prevalence of COVID-19 across Canada. Since the winter of 2021-22 with the onset of the Omicron wave, PCR testing for diagnosis of SARS-CoV-2 has failed to keep up with the rapid growth in infection across the population. The CITF has therefore drawn on serosurveillance studies (measuring antibodies due to infection and vaccination in a person’s blood) to provide updated estimates of the magnitude and trends in SARS-CoV-2 infection in Canada.” (Source: CITF) Along with more than 20 studies, blood spot samples from Atlantic PATH participants and CanPath participants across the country helped to inform work from the COVID-19 Immunity Task Force that found that 78.5% of Canadians had antibodies due to infection by April 30, 2023. You can find an interactive map prepared by the Data and Analysis Team at the COVID-19 Immunity Task Force here: https://www.covid19immunitytaskforce.ca/seroprevalence-in-canada/ COVID-19 Infection Induced Seroprevalence (Source: CITF) Although Atlantic Canada had the lowest infection rates inthe country through most of the pandemic, the increases seen during the spring and summer of 2022 resulted in a seroprevalence comparable to other regions by fall 2022. This was due to a rate of increase in Atlantic Canada during the early Omicron waves that was higher than other regions. Please visit CITF for additional details from this work: https://www.covid19immunitytaskforce.ca/seroprevalence-in-canada/ #PopulationHealth #Cohorts #HealthResearch

Pan-Canadian Cancer Data Strategy

Posted on July 18, 2023July 19, 2023 by pathwp

The Canadian Cancer Society (CCS) and Canadian Partnership Against Cancer (CPAC) have launched the Pan-Canadian Cancer Data Strategy that will guide efforts to enhance the collection, integration and use of cancer data. “CPAC and CCS have worked with various partners, including provincial and territorial cancer agencies and programs, healthcare organizations, First Nations, Inuit and Métis partners, researchers, policymakers and people with lived cancer experience to create a cancer-specific data strategy that includes: a framework to guide the mission, vision, values and success factors for improvements in cancer data three priorities for action and investment including: improving the efficiency, timeliness and quality of data capture and access enhancing linkages to current data filling gaps in current data collection and availability a section on the importance of First Nations, Inuit and Métis data sovereignty, with examples of First Nations, Inuit and Métis-led efforts to improve data and data governance.” CanPath, and its seven regional cohorts including Atlantic PATH, are proud to be represented in the new Pan-Canadian Cancer Data Strategy. We’re committed to filling gaps in data on risk factors to guide cancer prevention efforts. CPAC Press Release: https://www.partnershipagainstcancer.ca/about-us/corporate-resources-publications/pan-canadian-cancer-data-strategy/

CSEB Conference Update

Posted on July 7, 2023 by pathwp

The CanPath team was well represented at the Canadian Society for Epidemiology & Biostatistics (CSEB) Conference in Halifax on June 26-28, 2023. We had representatives from the CanPath National Coordinating Centre, Atlantic PATH, CARTaGENE, the Manitoba Tomorrow Project, and the Ontario Health Study that showcased the groundbreaking research and resources available related to epidemiology and biostatistics within CanPath and the regional cohorts. Throughout the conference, CanPath and the regional cohorts were well-represented in various sessions and discussions, particularly regarding data linkage. Some notable presentations included: ? Dr. Robin Urquhart, Scientific Director of Atlantic PATH, co-presented a workshop on data repositories in Canada ? Dr. Ellen Sweeney, Research Director of Atlantic PATH, presented at a concurrent session about research at Atlantic PATH exploring environmental exposure to arsenic and cancer risk using toxicological and machine-learning methods ? Dr. Vikki Ho, co-Scientific Director of CARTaGENE, co-presented a workshop on mentorship for junior faculty and funding opportunities ? Nicholas Cheng, PhD candidate at the Ontario Institute for Cancer Research, presented at a concurrent session about his research on leveraging population health cohorts to identify cancer biomarkers in blood up to seven years before diagnosis ? Poster sessions featured CanPath, the Manitoba Tomorrow Project, the Ontario Health Study, CARTaGENE, and more, showcasing the exceptional research happening at the regional level and how they can support epidemiological and biostatistical projects. Please connect with us to learn more about these projects. We are proud to contribute to advancing this critical field and look forward to continuing our efforts to drive positive health outcomes for all. #CSEBConference2023 #Epidemiology #Biostatistics #EveryoneCounts #HealthResearch #Cohort #PopulationHealth

CBC News Article

Posted on July 4, 2023 by pathwp

A Dalhousie University and McMaster University led project is highlighted in a recent CBC article. The New Frontiers in Research Fund supported research is focused on disparities in cancer incidence and outcomes in a Black Nova Scotian community (Shelburne, Nova Scotia). This research is truly interdisciplinary, incorporating natural and social sciences to consider the role of environmental, biological, genetic, socioeconomic, and lifestyle factors with the high cancer incidence and mortality in this community. Atlantic PATH will act as a comparison population using data and biological samples from Nova Scotia participants. Additional details about this project and the new Nova Scotia Environmental Racism Panel in the CBC Article by Josefa Cameron (July 2, 2023): https://bit.ly/44dw9cu

CanPath Representation at the Canadian Society for Epidemiology and Biostatistics Conference

Posted on June 26, 2023June 27, 2023 by pathwp

We’re so glad to have representation from Atlantic PATH, CARTaGENE, Manitoba Tomorrow Project, Ontario Health Study, and CanPath at the Canadian Society for Epidemiology and Biostatistics Conference in Halifax this week! CanPath and the regional cohorts are well represented in the following sessions: Monday, June 26, 2023 Workshop 1 – Mentorship for Junior Faculty and Funding Opportunities: How to Break into the Game as a Junior Faculty Member [Dr. Vikki Ho, Scientific Co-Director, CARTaGENE] Workshop 3 – Data Repositories in Canada: Overview and Data Access 101 [Dr. Robin Urquhart, Scientific Director, Atlantic PATH] Tuesday, June 27, 2023 Concurrent Sessions B5: Lifecourse and Chronic Disease Epidemiology – Leveraging population health cohorts to identify cancer biomarkers in blood up to seven years prior to diagnosis Presenter: Nicholas Chang, PhD candidate, OICR Poster Session The Impact of Alcohol Consumption and Single Nucleode Polymorphisms on the High Rates of Colorectal Cancer in Atlantic Canada Presenter: Carlee Feinstein, Research Assistant, St. FX Authors: Carlee A Feinstein, Derrick G Lee, Allison Walsh, Tiffany S Bondo The Manitoba Tomorrow Project: A Canadian Cohort Presented by: Dr. Travis Hrubeniuk, Project Lead, Manitoba Tomorrow Project Authors: Travis Hrubeniuk, Sachin Katyal, Donna Turner Canadian Partnership for Tomorrow’s Health (CanPath): Celebrang Compleng the Provincial Map and Cross-Province Data Linkage Presented by: Dr. John McLaughlin, Executive Director, CanPath Authors: John McLaughlin, Riaz Alvi, Philip Awadalla, Parveen Bhatti, Trevor Dummer, Jason Hicks, Vikki Ho, Grace Shen-Tu, Kimberly Skead, Ellen Sweeney, Donna Turner, Robin Urquhart, Jennifer Vena Examining the impact of inflammatory bowel disease on colorectal cancer risk in Atlantic Canada Presented by: Livia Clarke, Research Assistant, Dalhousie Medical School / St. FX Authors: Livia Clarke, Derrick Lee, Ellen Sweeney The Impact of Abnormal Sleep and Circadian Disruption on Atlantic Canada’s High Rate of Colorectal Cancer Presented by: Alison Walsh, Research Assistant, St. FX Authors: Alison J Walsh, Carlee A Feinstein, Tiffany S Bondoc, Megan K MacGillivray, Derrick G Lee The Ontario Health Study (OHS) Presented by: Sarah Salih, Data Analyst, Ontario Health Study Authors: Victoria Kirsh, Kimberly Skead, Kelly McDonald, Nancy Kreiger, Julian Lile, Karen Menard, John McLaughlin, Sutapa Mukherjee, Lyle Palmer, Vivek Goel, Mark Purdue, Sarah Salih, Philip Awadalla Smoking, aberrant DNA methylaon of the F2RL3 and AHRR genes, and lung cancer risk Presented by: Vikki Ho, Scientific Co-Director, CARTaGENE Authors: Alice Nguyen, Anita Koushiki, Laura Pelland-St. Pierre, Michael Pham, Romain Pasquet, Sherryl Tauylor, Delphine Bosson-Rieutort, Vikki Ho The influence of occupaonal risk factors on DNA methylaon in the AHRR and F2RL3 genes Presented by: Laura Pelland-St-Pierre Authors: Michael Pham, Laura Pelland-St-Pierre, Alice Nguyen, Romain Pasquet, Sherryl Taylor, Delphine Bosson-Rieutort, Anita Koushik, Vikki Ho Wednesday, June 28, 2023 Concurrent Session C5: Cancer Epidemiology II – Exploring Environmental Exposure to Arsenic and Cancer Risk in the Atlantic PATH Cohort using Toxicological and Machine Learning Methods Presenter: Dr. Ellen Sweeney, Research Director, Atlantic PATH Please feel free to contact Atlantic PATH, CanPath or any of the regional cohorts to learn more about these projects!

CanPath Access Office Hours

Posted on June 22, 2023 by pathwp

The CanPath Access Office invites researchers to an Office Hours session. This virtual series provides researchers with an opportunity to ask questions about CanPath data and biosamples and the access process. Members of the Access Office will be available to answer questions and demonstrate how to navigate the CanPath Portal and online application. Registration: https://us02web.zoom.us/meeting/register/tZYsc-ugqD8sH9QfdxDq2NPHtBttkD17yCz1#/registration

#PlaidForDad2023

Posted on June 16, 2023June 16, 2023 by pathwp

#PlaidForDad2023 — Prostate Cancer Awareness and Research Atlantic PATH welcomes our youngest team member(!) and continues the Plaid for Dad tradition raising awareness about prostate cancer in Canada. We have ongoing research on prostate cancer exploring environmental exposure to arsenic and cancer risk using toxicological and machine learning methods. This research stream has received and benefitted from funding from Nova Scotia Health, the Beatrice Hunter Cancer Research Institute, Prostate Cancer Canada, the Canadian Cancer Society, and the New Frontiers in Research Fund. Related publications to date include: Keltie, E., Hood, K., Cui, Y., Sweeney, E., Ilie, G., Adishesh, A., Dummer, T.J.B., Bharti, V., Kim, J.S. (2022). Arsenic speciation and metallomics profiling of human toenails as a biomarker to assess prostate cancer cases: Atlantic PATH cohort study. Frontiers in Public Health, 10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301242/ Hood, K., Sweeney, E., Ilie, G., Keltie, E., Kim, J.S. (2023). Toenail arsenic species and metallome profiles associated with breast, cervical, prostate, and skin cancer prevalence in the Atlantic Partnership for Tomorrow’s Health cohort. Frontiers in Public Health, Environmental Health and Exposome. https://www.frontiersin.org/articles/10.3389/fpubh.2023.1148283/full Smith, N., Keltie, E., Sweeney, E., Weerasinghe, S., MacPherson, K., Kim, J.S. (2022). Toenail speciation biomarkers in arsenic-releated disease: a feasibility study for investigating the association between arsenic expsosure and chronic disease. Ecotoxicology and Environmental Safety, 232. https://www.sciencedirect.com/science/article/pii/S0147651322001099 We have also conducted research on the mental health of prostate cancer survivors compared to those with no history of cancer and those with types of cancer. This work was supported by funding from the Beatrice Hunter Cancer Research Institute. Publications to date include: Ilie, G., Rutledge, R., Sweeney, E. (2020). Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer. Psycho-Oncology. https://onlinelibrary.wiley.com/doi/10.1002/pon.5244 Ilie, G., Rutledge, R., Sweeney, E. (2021). An examination of the role of socioeconomic status in the relationship between depression and prostate cancer survivorship in a population-based sample of men from Atlantic Canada. Oncology, 99(4). https://pubmed.ncbi.nlm.nih.gov/33486485/ Ilie, G., Rutledge, R., Sweeney, E. (2021). Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada. Current Oncology, 28(4). https://www.mdpi.com/1718-7729/28/4/246

Toenail arsenic species and metallome profiles associated with breast, cervical, prostate, and skin cancer prevalence in the Atlantic Partnership for Tomorrow’s Health cohort

Posted on June 15, 2023June 15, 2023 by pathwp

Authors: Kalli Hood, Ellen Sweeney, Gabriela Ilie, Erin Keltie, Jong Sung Kim Journal: Frontiers in Public Health, Sec. Environmental Health and Exposome Abstract: Introduction: Chronic exposure to arsenic through drinking water has been linked to several cancers. The metabolism of arsenic is thought to play a key role in arsenic-related carcinogenesis as metabolites of varying toxicity are produced and either stored in or excreted from the body. Atlantic Canada has the highest age-standardized incidence rates of all cancers in the country. This may be due to its high levels of environmental arsenic and the prevalence of unregulated private wells for water consumption. Here, we aimed to characterize the profiles of arsenic species and metallome in the toenails of four cancer groups, compare them to healthy participants (N = 338), and assess potential associations between the profiles with cancer prevalence. Methods: This study employed a case–control design. Toenail samples and questionnaire data from cases (breast, cervical, prostate, and skin cancers) and controls were sourced from the Atlantic Partnership for Tomorrow’s Health (PATH) cohort study. The levels of arsenic species were measured using Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) paired with High Performance Liquid Chromatography (HPLC) and total concentrations of metallome (23 metals) were determined by ICP-MS separately. Multivariate analyses were conducted to compare cases with controls within each cancer group. Results: Arsenic speciation profiles varied by cancer type and were significantly different between cases and controls in the breast (p = 0.0330), cervical (p = 0.0228), and skin (p = 0.0228) cancer groups. In addition, the profiles of metallome (nine metals) were significantly differentiated in the prostate (p = 0.0244) and skin (p = 0.0321) cancer groups, with higher zinc concentrations among cases compared to controls. Conclusion: History of cancer diagnosis was associated with specific profiles of arsenic species and metallome. Our results indicate that arsenic methylation and zinc levels, as measured in toenails, may be an important biomarker for cancer prevalence. Further research is needed to use toenails as a prognostic measure of arsenic-and other metal-induced cancer. doi: https://doi.org/10.3389/fpubh.2023.1148283

New Toxicology Publication

Posted on June 15, 2023June 15, 2023 by pathwp

Congratulations to Kalli Hood and team on their new publication in Frontiers in Public Health! Kalli’s Master’s research found an association between a history of cancer and arsenic speciation/metallome exposure in the Atlantic PATH cohort. This work is part of our larger focus on environment and cancer, and establishing toenails as an important biomarker representing ~18 months of exposure. Kalli is now working on her PhD focused on drinking water quality in the Department of Civil and Resource Engineering at Dalhousie University.

Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Posted on May 31, 2023 by pathwp

Dr. Victoria Kirsh presented at a CanPath webinar this week to present results from the SUPPORT-Canada study, funded by the federal COVID-19 Immunity Task Force (CITF). Data and blood spot samples were used from 22,300 participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations. Key findings include: 62% of participants had a COVID-19 infection based on anti-N measured antibody levels. Among those, 86% did not suspect they had ever had COVID-19. 95% of the COVID-19 infections were observed during the Omicron period. Risk of infection was increased among younger individuals, males, essential workers, and those who travelled. Participants with a reported COVID-19 infection reported symptoms from mild to severe, but few required hospitalization. The effectiveness of full or booster vaccination in preventing COVID-19 Omicron infection is short-term, only lasting 4 months. Time since last dose is a more important determinant of protection against infection than the number of doses. Antibody levels are correlates of vaccine-induced protection. Prior COVID-19 infection protects against reinfection for 8 months. The CanPath SUPPORT-Canada study has provided important findings related to the COVID-19 pandemic, vaccines and infections. With only 4 months of protection, these findings suggest that booster campaigns could be strategically used to rapidly boost immunity before upcoming waves of infection. Further, the longitudinal nature of CanPath participants ensures that we have a nationally representative population that can be followed for years to come (e.g., impact of Long COVID, future vaccinations, etc.). Link to recorded webinar: To come Link to webinar slide deck: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/05/canpath-webinar-may-2023.pdf Link to CITF’s post: https://www.covid19immunitytaskforce.ca/most-canpath-study-participants-had-infection-acquired-antibodies-but-few-suspected-covid-19/